A new type of antibiotic for treating urinary tract infections (UTIs) may be available sooner than expected. Gepotidacin, manufactured by the pharmaceutical company GSK, is being described as “novel” or “first-in-class” because of how it works to prevent or slow bacterial DNA replication. If approved, gepotidacin would be the first new antibiotic developed for treating UTIs in more than 20 years. It would also be available at least a year ahead of the estimated study completion date. Read more.

Source: healthline, November 8, 2022